secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2026-07-10T12:00:24+00:00
Accession:  0001493152-26-032777
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharmaceuticals reports positive preclinical results for MIRA-55 oral formulation for chronic pain
--------------------------------------------------------------------------------

- Selected lead oral formulation of MIRA-55 with favorable oral bioavailability and sustained systemic exposure.
- Formulation demonstrated reproducible distribution into brain and liver tissue after oral administration.
- Prior studies showed oral MIRA-55 normalized pain and reduced inflammation, outperforming injected morphine.
- MIRA-55 exhibited anxiolytic activity and no THC-like CNS effects; interacts with cannabinoid system distinct from THC.
- Company plans further preclinical evaluation of tissue exposure, pharmacodynamic activity, and therapeutic efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226032777/0001493152-26-032777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315226032777/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-032777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer